^
    Back
    Association details:
    Biomarker:BAP1 mutation
    Cancer:Cholangiocarcinoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    gemcitabine (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    PLoS One
    Title:

    Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

    Excerpt:
    All patients selected were those with pathologically confirmed CCA and a minimum of 3 months of follow-up….all cases with BAP1 mutation were treated with systemic chemotherapy consisting of gemcitabine and cisplatin. No radiologic response was noted and progression after first line chemotherapy occurred in all cases within a short time frame (less than 4 months).
    DOI:
    https://dx.doi.org/10.1371%2Fjournal.pone.0115383